Reclast® (zoledronic acid)

Covers Reclast (zoledronic acid) for FDA‑approved uses (treatment/prevention of postmenopausal osteoporosis, treatment of osteoporosis in men, treatment/prevention of glucocorticoid‑induced osteoporosis, Paget’s disease) and the compendial off‑label use osteogenesis imperfecta; other non‑compendial off‑label uses are excluded. Approval requires specific clinical documentation (T‑scores or fracture history, serum alkaline phosphatase for Paget’s, evidence of glucocorticoid use or OI diagnosis), generally a 12‑month trial of an oral bisphosphonate unless intolerant/unable, adherence to dosing/frequency limits (typically 5 mg IV yearly for treatment, every 2 years for prevention, single 5 mg for Paget’s, specified pediatric dosing for OI), and reauthorization requires stability or improvement (and ≥24 months since last dose for prevention).

"Treatment and prevention of osteoporosis in postmenopausal women"